vs
Healthpeak Properties（DOC）与特诺控股（TROX）财务数据对比。点击上方公司名可切换其他公司
特诺控股的季度营收约是Healthpeak Properties的1.1倍（$760.0M vs $702.9M），特诺控股同比增速更快（4.1% vs -6.6%），过去两年Healthpeak Properties的营收复合增速更高（0.5% vs -3.7%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
特诺控股是一家业务遍及全球的美国化工企业，专注于钛制品领域，现有员工约6500名。在收购南非埃萨罗资源原有的矿砂业务后，特诺已成为全球规模最大的全产业链二氧化钛颜料供应商。二氧化钛颜料主要为涂料、塑料、纸张等产品增白增亮，特诺还拥有钛矿砂开采及加工业务。
DOC vs TROX — 直观对比
营收规模更大
TROX
是对方的1.1倍
$702.9M
营收增速更快
TROX
高出10.8%
-6.6%
两年增速更快
DOC
近两年复合增速
-3.7%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $702.9M | $760.0M |
| 净利润 | $363.0M | — |
| 毛利率 | — | 0.0% |
| 营业利润率 | 0.7% | — |
| 净利率 | 51.6% | — |
| 营收同比 | -6.6% | 4.1% |
| 净利润同比 | 28.3% | — |
| 每股收益（稀释后） | $0.28 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCTROX
| Q1 26 | $702.9M | $760.0M | ||
| Q4 25 | $719.4M | $730.0M | ||
| Q3 25 | $705.9M | $699.0M | ||
| Q2 25 | $694.3M | $731.0M | ||
| Q1 25 | $702.9M | $738.0M | ||
| Q4 24 | $698.0M | $676.0M | ||
| Q3 24 | $700.4M | $804.0M | ||
| Q2 24 | $695.5M | $820.0M |
净利润DOCTROX
| Q1 26 | $363.0M | — | ||
| Q4 25 | $114.0M | $-176.0M | ||
| Q3 25 | $-117.1M | $-99.0M | ||
| Q2 25 | $31.7M | $-84.0M | ||
| Q1 25 | $42.8M | $-111.0M | ||
| Q4 24 | $4.5M | $-30.0M | ||
| Q3 24 | $85.9M | $-25.0M | ||
| Q2 24 | $146.0M | $16.0M |
毛利率DOCTROX
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 5.3% | ||
| Q3 25 | 58.6% | 7.4% | ||
| Q2 25 | 60.2% | 10.8% | ||
| Q1 25 | 61.1% | 13.4% | ||
| Q4 24 | 60.3% | 17.3% | ||
| Q3 24 | 60.0% | 15.9% | ||
| Q2 24 | 60.6% | 18.3% |
营业利润率DOCTROX
| Q1 26 | 0.7% | — | ||
| Q4 25 | 17.4% | -15.6% | ||
| Q3 25 | 9.2% | -6.2% | ||
| Q2 25 | 5.7% | -4.8% | ||
| Q1 25 | 7.7% | -8.3% | ||
| Q4 24 | -2.2% | 7.1% | ||
| Q3 24 | 14.1% | 6.7% | ||
| Q2 24 | 22.3% | 9.3% |
净利率DOCTROX
| Q1 26 | 51.6% | — | ||
| Q4 25 | 73.2% | -24.1% | ||
| Q3 25 | -16.6% | -14.2% | ||
| Q2 25 | 4.6% | -11.5% | ||
| Q1 25 | 6.1% | -15.0% | ||
| Q4 24 | 0.7% | -4.4% | ||
| Q3 24 | 12.3% | -3.1% | ||
| Q2 24 | 21.0% | 2.0% |
每股收益（稀释后）DOCTROX
| Q1 26 | $0.28 | — | ||
| Q4 25 | $0.16 | $-1.11 | ||
| Q3 25 | $-0.17 | $-0.63 | ||
| Q2 25 | $0.05 | $-0.53 | ||
| Q1 25 | $0.06 | $-0.70 | ||
| Q4 24 | $0.02 | $-0.19 | ||
| Q3 24 | $0.12 | $-0.16 | ||
| Q2 24 | $0.21 | $0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $-1.2B | $126 |
| 总债务越低越好 | — | $133 |
| 股东权益账面价值 | $7.8B | $1.3K |
| 总资产 | $21.6B | $6.1K |
| 负债/权益比越低杠杆越低 | — | 0.10× |
8季度趋势，按日历期对齐
现金及短期投资DOCTROX
| Q1 26 | $-1.2B | $126 | ||
| Q4 25 | $467.5M | $199.0M | ||
| Q3 25 | $91.0M | $185.0M | ||
| Q2 25 | $89.4M | $132.0M | ||
| Q1 25 | $70.6M | $138.0M | ||
| Q4 24 | $119.8M | $151.0M | ||
| Q3 24 | $180.4M | $167.0M | ||
| Q2 24 | $106.9M | $201.0M |
总债务DOCTROX
| Q1 26 | — | $133 | ||
| Q4 25 | $9.8B | $3.1B | ||
| Q3 25 | $9.1B | $3.1B | ||
| Q2 25 | $9.0B | $2.7B | ||
| Q1 25 | $8.9B | $2.8B | ||
| Q4 24 | $8.7B | $2.8B | ||
| Q3 24 | $8.6B | $2.8B | ||
| Q2 24 | $8.6B | $2.8B |
股东权益DOCTROX
| Q1 26 | $7.8B | $1.3K | ||
| Q4 25 | $7.5B | $1.4B | ||
| Q3 25 | $7.6B | $1.6B | ||
| Q2 25 | $7.9B | $1.6B | ||
| Q1 25 | $8.2B | $1.7B | ||
| Q4 24 | $8.4B | $1.8B | ||
| Q3 24 | $8.6B | $1.9B | ||
| Q2 24 | $8.8B | $1.9B |
总资产DOCTROX
| Q1 26 | $21.6B | $6.1K | ||
| Q4 25 | $20.3B | $6.2B | ||
| Q3 25 | $19.6B | $6.3B | ||
| Q2 25 | $19.8B | $6.2B | ||
| Q1 25 | $19.8B | $6.1B | ||
| Q4 24 | $19.9B | $6.0B | ||
| Q3 24 | $20.0B | $6.2B | ||
| Q2 24 | $20.2B | $6.1B |
负债/权益比DOCTROX
| Q1 26 | — | 0.10× | ||
| Q4 25 | 1.31× | 2.21× | ||
| Q3 25 | 1.20× | 2.01× | ||
| Q2 25 | 1.14× | 1.67× | ||
| Q1 25 | 1.08× | 1.64× | ||
| Q4 24 | 1.04× | 1.57× | ||
| Q3 24 | 1.00× | 1.45× | ||
| Q2 24 | 0.98× | 1.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | — | $53.0M |
| 自由现金流率自由现金流/营收 | — | 7.0% |
| 资本支出强度资本支出/营收 | 3.4% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-86.0M |
8季度趋势，按日历期对齐
经营现金流DOCTROX
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $121.0M | ||
| Q3 25 | $315.0M | $-57.0M | ||
| Q2 25 | $363.5M | $28.0M | ||
| Q1 25 | $279.4M | $-32.0M | ||
| Q4 24 | $1.1B | $82.0M | ||
| Q3 24 | $318.2M | $87.0M | ||
| Q2 24 | $316.2M | $160.0M |
自由现金流DOCTROX
| Q1 26 | — | $53.0M | ||
| Q4 25 | $357.0M | $53.0M | ||
| Q3 25 | — | $-137.0M | ||
| Q2 25 | — | $-55.0M | ||
| Q1 25 | — | $-142.0M | ||
| Q4 24 | $333.7M | $-35.0M | ||
| Q3 24 | — | $-14.0M | ||
| Q2 24 | — | $84.0M |
自由现金流率DOCTROX
| Q1 26 | — | 7.0% | ||
| Q4 25 | 49.6% | 7.3% | ||
| Q3 25 | — | -19.6% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | -19.2% | ||
| Q4 24 | 47.8% | -5.2% | ||
| Q3 24 | — | -1.7% | ||
| Q2 24 | — | 10.2% |
资本支出强度DOCTROX
| Q1 26 | 3.4% | 0.0% | ||
| Q4 25 | 124.4% | 9.3% | ||
| Q3 25 | — | 11.4% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 14.9% | ||
| Q4 24 | 105.6% | 17.3% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 9.3% |
现金转化率DOCTROX
| Q1 26 | — | — | ||
| Q4 25 | 10.99× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 11.48× | — | ||
| Q1 25 | 6.52× | — | ||
| Q4 24 | 235.43× | — | ||
| Q3 24 | 3.71× | — | ||
| Q2 24 | 2.17× | 10.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
| Outpatient Medical | $320.5M | 46% |
| Lab | $217.6M | 31% |
| Senior Housing | $148.9M | 21% |
| Other | $14.3M | 2% |
| Corporate Non-segment | $1.5M | 0% |
TROX
暂无分部数据
